Arshad Iqbal, MD
Neurology · Warwick, RINPI 1174564983
Payments from drug & device makers
What this record shows
This record is dominated by grants: $20,000 of the $21,162 with a category attached, or 94.5%. Medtronic accounts for 94.5% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2020 at $10,142 and has fallen 95.5% since, to $452 in 2025.
Across 47 payments — averaging $450.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$20K
- Eisai Inc.$141
- CSL Behring$125
- Neurelis, Inc.$111
- AbbVie$94
- Otsuka America Pharmaceutical, Inc.$90
- plus $601 from 17 others
What the payments were for
- Grants$20,00095%
- Food & beverage$1,1295%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 2 | $20,000 |
| Eisai Inc. | 2 | $141 |
| CSL Behring | 1 | $125 |
| Neurelis, Inc. | 5 | $111 |
| AbbVie(2 entities) | 5 | $94 |
| Otsuka America Pharmaceutical, Inc. | 4 | $90 |
| EMD Serono, Inc. | 3 | $70 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| Cycle Pharmaceuticals Inc | 2 | $51 |
| Novartis | 3 | $49 |
| Abbott | 1 | $45 |
| Insightec,inc | 2 | $39 |
| Biogen | 2 | $36 |
| Pfizer | 2 | $36 |
| MDD US Operations, LLC | 1 | $35 |
| SK Life Science, Inc. | 1 | $35 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $33 |
| UCB, Inc. | 1 | $25 |
| Livanova USA, Inc. | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Life Molecular Imaging Ltd | 1 | $18 |
| Noctrix Health, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,162 in reported general payments places this provider in the 80th percentile of 86 neurology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlatopaGlatiramer Acetate | 27 | $86,824 |
| Nurtec OdtRimegepant Sulfate | 19 | $23,572 |
| Aimovig AutoinjectorErenumab-Aooe | 18 | $13,261 |
| Levetiracetam | 273 | $11,893 |
| Donepezil Hcl | 354 | $7,947 |
| Rivastigmine | 19 | $6,059 |
| Levetiracetam ErLevetiracetam | 46 | $6,007 |
| Memantine Hcl | 126 | $5,927 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 181 | $5,837 |
| Divalproex Sodium ErDivalproex Sodium | 51 | $5,405 |
| Carbamazepine ErCarbamazepine | 45 | $4,726 |
| Rasagiline Mesylate | 26 | $4,501 |
| DilantinPhenytoin Sodium Extended | 23 | $4,353 |
| Lacosamide | 25 | $3,713 |
| Primidone | 82 | $2,745 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Dilantin | $36 | $27,92542 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 86 neurology providers in Rhode Island.
Other neurology in Warwick
- Gary LeuropaWarwick$7K
- Adam DrobnisWarwick$4K
- Keith BrecherWarwick$4K
- Mauricio VillamarWarwick$798
- Stephen SallowayProvidence$329K
- Peter BellafioreWakefield$274K
- Norman GordonEast Providence$206K
- Syed RizviProvidence$160K
- Albert MaranoJohnston$145K
- John EastonProvidence$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.